Physician profile
Matthew Stuart
NPI 1396159448
$3,354.14
in general payments reported to CMS, 2019-2025
53 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $542 · 2022: $537 · 2023: $864 · 2024: $456 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $84.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.49 |
| Education | $84.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $277.74 | 2021-2025 | |
| Abbvie INC. | $275.57 | 2021-2025 | Venclexta |
| Incyte Corporation | $248.08 | 2021-2025 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $169.11 | 2021-2025 | Imfinzi, Enhertu |
| Pharmacosmos Therapeutics INC. | $160.93 | 2023-2025 | Monoferric |
| Glaxosmithkline, LLC. | $138.71 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $138.30 | 2020-2024 | Tecvayli, Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $132.35 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $110.25 | 2020-2025 | Opdivo, Reblozyl |
| Pfizer INC. | $103.09 | 2023-2024 | |
| Genentech USA, INC. | $103.03 | 2022-2025 | Tecentriq, Alecensa, Polivy |
| Array Biopharma INC | $101.16 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $91.35 | 2021-2023 | Kyprolis, Lumakras |
| Daiichi Sankyo INC. | $87.34 | 2021-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $86.34 | 2021-2025 | Brukinsa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.